effect overlay
activetrials
Epilepsy
Epilepsy
seLECT - SEL004

A Phase 2, Randomised, Controlled Trial of Sodium Selenate as a Disease-modifying Treatment for Chronic Drug-resistant Temporal Lobe Epilepsy 
 

HREC: 2023.153
Principal Investigator: Dr John-Paul Nicolo
Coordinator contact: Lei Chen
Funding: Non-Commercial